entertainment -WSS

entertainment

author：Wikipedia 2025-08-23 06:54:26 - browse：7

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Pfizer is about to make a big push in cancer. Will investors listen?

focus

WSS

AI models in health care face new federal disclosure requirements

What PEPFAR has meant on the ground in Ukraine

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Pfizer is about to make a big push in cancer. Will investors listen?

FDA needs staff influx to meet gene therapy needs, Marks says

CDC panel: People 65 and older should get a Covid spring booster shot

explore

entertainment

explore

Anesthesiologist group: stop taking Ozempic before surgery

5 ways to address the shortage of health care workers

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Moonlake's readout produced a cash windfall. Risks remain

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Medicare details structure of new drug price negotiation program

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Dobbs anniversary: the lost opportunity of abortion as health care

Study fuels hope CAR

Wikipedia

What causes an itch? Researchers may have solved the mystery

SCOTUS to consider access to abortion pill mifepristone

Children’s Hospital revives plan for pedestrian bridge

Childhood vaccination ad campaign launches in the U.K.

Leukemia patients are helped by Syndax's new type of therapy

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

hotspot

focus

focus

knowledge